Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring studyjeanfrancoismaison2 days ago1 min readRated NaN out of 5 stars.https://pubmed.ncbi.nlm.nih.gov/40288377/
Paving the path ForwARd: Advances and challenges in androgen receptor targeting in breast cancerhttps://pubmed.ncbi.nlm.nih.gov/40424861/
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directionshttps://pubmed.ncbi.nlm.nih.gov/40429716/
Facing the Challenge to Mimic Breast Cancer Heterogeneity: Established and Emerging Experimental Preclinical Models Integrated with Omics Technologieshttps://pubmed.ncbi.nlm.nih.gov/40429718/
Comments